MA29683B1 - Combinaison pour traiter une hyperplasie benigne de la prostate - Google Patents

Combinaison pour traiter une hyperplasie benigne de la prostate

Info

Publication number
MA29683B1
MA29683B1 MA30335A MA30335A MA29683B1 MA 29683 B1 MA29683 B1 MA 29683B1 MA 30335 A MA30335 A MA 30335A MA 30335 A MA30335 A MA 30335A MA 29683 B1 MA29683 B1 MA 29683B1
Authority
MA
Morocco
Prior art keywords
hyperplasie
benign
prostate
treating
combination
Prior art date
Application number
MA30335A
Other languages
English (en)
Inventor
Helmut Haning
Peter Serno
Erwin Bischoff
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of MA29683B1 publication Critical patent/MA29683B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

Combinaison pour traiter une hyperplasie bénigne de la prostate Cette invention se rapporte à un nouveau procédé pour le traitement des symptômes associés à l'hyperplasie bénigne de la prostate couramment employé pour traiter médicalement l'hyperplasie bénigne de la prostate. Ceci nécessite l'utilisation concomitante : (1) d'un antagoniste des récepteurs (alpha)1-adrénergiques dans une formulation à libération contrôlée ou d'un inhibiteur de la 5-(alpha) réductase et (2) d'un inhibiteur de la PDE 5 spécifique de la GMPc dans une formulation à libération contrôlée ou d'un inhibiteur de la PDE 5 spécifique de la GMPc avec une longue demi-vie.
MA30335A 2005-04-13 2007-10-29 Combinaison pour traiter une hyperplasie benigne de la prostate MA29683B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005016981A DE102005016981A1 (de) 2005-04-13 2005-04-13 Kombination zur Therapie bei benigner Prostatahyperplasie

Publications (1)

Publication Number Publication Date
MA29683B1 true MA29683B1 (fr) 2008-08-01

Family

ID=36608700

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30335A MA29683B1 (fr) 2005-04-13 2007-10-29 Combinaison pour traiter une hyperplasie benigne de la prostate

Country Status (22)

Country Link
EP (1) EP1888075A1 (fr)
JP (1) JP2008535877A (fr)
KR (1) KR20080007252A (fr)
CN (1) CN101193638A (fr)
AR (1) AR053575A1 (fr)
AU (1) AU2006233567A1 (fr)
BR (1) BRPI0610634A2 (fr)
CA (1) CA2605224A1 (fr)
CR (1) CR9427A (fr)
DE (1) DE102005016981A1 (fr)
DO (1) DOP2006000074A (fr)
GT (1) GT200600145A (fr)
IL (1) IL186604A0 (fr)
MA (1) MA29683B1 (fr)
MX (1) MX2007012567A (fr)
PE (1) PE20061338A1 (fr)
RU (1) RU2007141518A (fr)
SV (1) SV2008002477A (fr)
TN (1) TNSN07385A1 (fr)
TW (1) TW200716122A (fr)
UY (1) UY29473A1 (fr)
WO (1) WO2006108519A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
US20070093493A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
US20080261995A1 (en) * 2005-12-21 2008-10-23 Pfizer Inc. Pharmaceutical Combination of a Pde-5 Inhibitor and a 5-Alpha Reductase Inhibitor
WO2008005039A1 (fr) * 2006-07-07 2008-01-10 Teva Pharmaceutical Industries Ltd. Compositions solides comprenant du tadalafil et au moins un véhicule
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
NZ585923A (en) 2007-12-13 2012-09-28 Vanda Pharmaceuticals Inc Use of 4-[3-[4-(6-fluoro-1,2,-benzisoxazol-3-yl)-1-piperidinyl]propoxy]-3-methoxy-benzoic acid for treating a condition that is mediated by a 5-HT2A receptor
WO2009076663A1 (fr) 2007-12-13 2009-06-18 Vanda Pharmaceuticals Inc. Procédé et composition pour traiter une affection véhiculée par alpha-adrénocepteur
US8654746B2 (en) 2010-04-26 2014-02-18 Intel Corporation Method, apparatus and system for fast session transfer for multiple frequency band wireless communication
WO2013123965A1 (fr) * 2012-02-20 2013-08-29 Synthon Bv Formulation pharmaceutique à dose fixe
CN102727456B (zh) * 2012-07-03 2016-06-22 北京科信必成医药科技发展有限公司 药物口腔崩解片及其制备方法
CN105338970B (zh) * 2013-06-28 2019-07-09 韩美药品株式会社 包含他达拉非和坦洛新的药物胶囊复合制剂
DK3024474T3 (da) 2013-07-23 2022-03-28 Serenity Pharmaceuticals Llc Sammensætninger omfattende desmopressin i kombination med en beta-3-adrenoreceptor-agonist
KR101663238B1 (ko) * 2013-11-15 2016-10-14 한미약품 주식회사 타다라필 및 암로디핀을 포함하는 복합 고형 제제
CN106659690B (zh) * 2014-06-30 2020-08-18 韩美药品株式会社 包括含有活性成分的膜包衣层的复合制剂
WO2016003181A1 (fr) * 2014-06-30 2016-01-07 한미약품 주식회사 Préparation composite comprenant une couche de revêtement par film contenant un principe actif
WO2016003180A1 (fr) * 2014-06-30 2016-01-07 한미약품 주식회사 Preparation composite comprenant une couche de revêtement pelliculaire contenant un inhibiteur de la 5-alpha-réductase, et procédé pour produire la préparation composite
KR20170097045A (ko) * 2014-11-20 2017-08-25 알레간 인코포레이티드 알파-아드레날린성 수용체 길항제와 조합된 데스모프레신을 포함하는 방법 및 조성물
JP2019510071A (ja) * 2016-03-31 2019-04-11 ハンミ ファーマシューティカルズ カンパニー リミテッド 安定性及び溶出率が改善されたタダラフィル含有及びタムスロシン含有のカプセル複合製剤
KR101835506B1 (ko) * 2016-10-25 2018-03-07 주식회사 에스텍파마 두타스테리드와 타다라필을 함유하는 속효성 복합정제
CN108066347B (zh) * 2016-11-16 2021-02-02 深圳万和制药有限公司 包含坦索罗辛和度他雄胺的口腔崩解片药物组合物
KR101879133B1 (ko) * 2017-07-11 2018-07-17 (주)동구바이오제약 비뇨기 질환 예방 또는 치료용 제제 및 이의 제조방법
TR201715231A2 (tr) * 2017-10-09 2019-04-22 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Dapokseti̇n ve fosfodi̇esteraz ti̇p-5 i̇nhi̇bi̇törü i̇çeren farmasöti̇k kombi̇nasyon

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base

Also Published As

Publication number Publication date
AU2006233567A1 (en) 2006-10-19
DOP2006000074A (es) 2006-10-15
SV2008002477A (es) 2008-02-08
TNSN07385A1 (en) 2009-03-17
CR9427A (es) 2007-12-17
UY29473A1 (es) 2006-11-30
CA2605224A1 (fr) 2006-10-19
DE102005016981A1 (de) 2006-10-19
GT200600145A (es) 2007-04-10
JP2008535877A (ja) 2008-09-04
RU2007141518A (ru) 2009-05-20
KR20080007252A (ko) 2008-01-17
MX2007012567A (es) 2007-12-10
PE20061338A1 (es) 2007-01-28
IL186604A0 (en) 2008-01-20
EP1888075A1 (fr) 2008-02-20
AR053575A1 (es) 2007-05-09
TW200716122A (en) 2007-05-01
WO2006108519A1 (fr) 2006-10-19
CN101193638A (zh) 2008-06-04
BRPI0610634A2 (pt) 2010-07-13

Similar Documents

Publication Publication Date Title
MA29683B1 (fr) Combinaison pour traiter une hyperplasie benigne de la prostate
MA31150B1 (fr) Antagonistes spécifiques de vegf pour thérapie par adjuvant et néoadjuvant et traitement de tumeurs de premier stade
ATE394400T1 (de) Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
ATE509019T1 (de) Benzodiazepinspirohydantoine als cgrp- rezeptorantagonisten
FR16C0021I2 (fr) Azetidines en tant qu'inhibiteurs de mek et leur utilisation pour le traitement des maladies proliferatives
MA27548A1 (fr) Inhibiteurs heterocycliques beta-amines de la dipeptidyl peptidase pour le traitement ou la prevention du diabete.
NO20054411L (no) Terapeutiske midler omfattende et anti-angiogent middel i kombinasjon med en SRC-inhibitor og deres terapeutiske anvendelse
NO20072322L (no) Laktamforbindelser og anvendelse derav som farmasoytiske midler
TW200505903A (en) CGRP receptor antagonists
MA29713B1 (fr) Derives de tetrahydroindolone et de tetrahydroindazolone
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de) Azolylaminoazine als proteinkinasehemmer
MA27556A1 (fr) Derives de phenylalanine comme inhibiteurs de la dipeptidyl peptidase pour le traitement ou la prevention du diabete
ATE464305T1 (de) Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
MA29915B1 (fr) Benzimidazoles substitues utilises en tant qu'inhibiteurs de kinases
EP1613368A4 (fr) Antagonistes des recepteurs du cgrp a base de carboxamide spirohydantoine
EA200700251A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
ATE483692T1 (de) Als beta-sekretase (bace)-hemmer nützliche 2- amino-chinazolinderivate
EP1606264A4 (fr) Antagonistes des recepteurs du cgrp d'anilide spirohydantoine monocyclique
NO20065442L (no) Amidoforbindelser og deres anvendelse som legemidler
ATE516803T1 (de) Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
ATE532781T1 (de) 5-(acylamino)indazol-derivate als kinase- inhibitoren
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
PE20011167A1 (es) Composiciones farmaceuticas que comprenden un antagonista del alfa-adrenoreceptor y un antagonista muscarinico para el tratamiento de hiperplasia prostatica benigna
MA29880B1 (fr) Inhibiteurs pde et combinaisons de ceux-ci pour traiter des troubles urinaires.